Manfred Welslau, MD

Manfred Welslau, MD, discusses the rationale of the prospective REFLECT trial with the rituximab biosimilar SDZ-RTX in patients with diffuse large B-cell lymphoma.

Manfred Welslau, MD, discusses​ the interim results of the REFLECT trial in diffuse large B-cell lymphoma.

Manfred Welslau, MD, discusses​ the potential benefits of ​using biosimilars in diffuse large B-cell lymphoma.

Manfred Welslau, MD, discusses the rationale for investigating the Sandoz rituximab biosimilar, Rixathon, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Manfred Welslau, MD, discusses the first interim safety analysis in treatment-naïve, CD20-positive diffuse large B-cell lymphoma following the approval of Rixathon, a Sandoz biosimilar for rituximab.

Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses the rationale for the REFLECT trial in diffuse large B-cell lymphoma.

Manfred Welslau, MD, discusses financial savings of using a rituximab biosimilar for patients with previously untreated CD20-positive diffuse large B-cell lymphoma.

Manfred Welslau, MD, Internal Medicine, Hematology and Oncology, Onkologie Aschaffenburg, discusses the growing acceptance of a rituximab (Rituxan) biosimilar in the treatment of patients with diffuse large B-cell lymphoma, following favorable results from a safety analysis of the REFLECT study.